New Delhi, July 25, 2014 – Pharmaceutical firm Strides Arcolab has received the regulatory approval to market Tacrolimus capsules in the US market.
The capsule is an immuno-suppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant.The company has been allowed by United States Food and Drug Administration (USFDA) to sell Tacrolimus capsules in the strengths of 0.5 mg, 1 mg and 5 mg, Strides Arcolab said in a BSE filing.
The US market for generic Tacrolimus is approximately USD 676 million, the company said, citing IMS data.”The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed directly by Strides in the US market,” the company said in a statement.
Strides Arcolab’s shares were trading 0.62 per cent down at Rs 670 apiece during afternoon trade on the BSE.
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…
Nagpur, April 03, 2024: HCG Cancer Center Nagpur has launched a one-of-a-kind indigenous Asia`s first…
New Delhi, March 22nd, 2024: Manipal Hospital, Dwarka, in association with the Indian Academy of Pediatrics…